secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acrivon Therapeutics, Inc. (ACRV)
CIK:        0001781174
Form:       8-K
Filed at:   2024-06-21T23:59:59+00:00
Accession:  0000950170-24-075760
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Acrivon Therapeutics stockholders elect three Class II directors and ratify PwC as auditor at 2024 annual meeting
--------------------------------------------------------------------------------

- Kristina Masson, Sharon Shacham, and Ivana Magovčević-Liebisch were elected as Class II directors with 24.6M, 23.3M, and 24.5M votes in favor, respectively.
- PricewaterhouseCoopers LLP was ratified as independent auditor for fiscal year 2024 with 27.4M for, 6,036 against, and 10,308 abstentions.
- A quorum of 27.4M shares (88.81% of outstanding) was present or represented by proxy at the June 20, 2024 annual meeting.
- Broker non-votes on director elections totaled approximately 2.7M shares, with none on auditor ratification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024075760/0000950170-24-075760-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781174/000095017024075760/acrv-20240620.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-075760

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer